Inhaler use for cough treatment
Pro Research Analysisby 
Searched over 200M research papers
Inhaler Use for Cough Treatment: Effectiveness and Options
Inhaled Corticosteroids for Chronic Cough and Cough Variant Asthma
Inhaled corticosteroids (ICS), such as budesonide, beclomethasone, and fluticasone, are widely used for treating chronic cough and cough variant asthma (CVA). Studies show that high-dose inhaled beclomethasone leads to complete cough resolution in a significant proportion of patients with chronic cough, even when the cough is not linked to atopy or airway hyperresponsiveness . Budesonide-formoterol inhalers have also demonstrated high effectiveness, with over 86% of patients with CVA experiencing improvement in cough symptoms . In children with CVA, fluticasone propionate inhalation effectively controls cough, and longer treatment durations (at least six months) reduce the risk of relapse after stopping the medication . Budesonide inhalation, when combined with conventional symptomatic treatment, significantly reduces inflammation and improves lung function in CVA patients . For adults with chronic cough and elevated fractional exhaled nitric oxide (FeNO), a short-term trial of high-dose fluticasone furoate can improve cough severity and quality of life for most patients .
Inhaler Device Type: Dry Powder Inhaler (DPI) vs. Metered Dose Inhaler (MDI)
The type of inhaler device—DPI or MDI—does not significantly affect the efficacy of cough treatment in patients with cough variant or cough-predominant asthma. Both devices are equally effective in controlling cough and improving quality of life. However, switching inhaler types, combined with proper inhalation technique training, can further improve asthma control and reduce cough severity .
Inhaled Bronchodilators and Lidocaine for Cough Suppression
For patients with chronic obstructive pulmonary disease (COPD) experiencing intractable cough, both nebulized lidocaine and bronchodilator inhalation (such as terbutaline) are effective for rapid, short-term cough suppression. Both treatments significantly reduce cough severity within an hour, with only mild and transient side effects reported .
Novel and Adjunct Inhaled Therapies for Refractory Cough
Emerging inhaled therapies are being explored for patients with refractory or disease-specific cough. Inhaled alkaline hypertonic divalent salts (HDS) have shown promise in reducing cough frequency in patients with refractory chronic cough, especially at higher pH levels, with no reported adverse events . Inhaled sodium cromoglicate (PA101) has been effective in reducing cough frequency in patients with idiopathic pulmonary fibrosis (IPF), but not in those with chronic idiopathic cough, suggesting disease-specific benefits .
Combination Inhaler Therapies for Persistent Asthma-Related Cough
For asthma patients whose cough persists despite medium-dose ICS/long-acting β2-agonist (LABA) therapy, switching to a combination inhaler containing indacaterol, glycopyrronium, and mometasone (IND/GLY/MF) is being studied as a potential strategy to further improve cough-specific quality of life and reduce cough severity .
Conclusion
Inhaler therapies, especially those containing corticosteroids, are effective for treating various types of cough, including chronic cough, cough variant asthma, and cough associated with COPD. The choice between DPI and MDI devices does not significantly impact treatment outcomes, but proper inhaler technique and device switching may enhance results. Novel inhaled treatments and combination therapies are expanding options for patients with refractory or disease-specific cough. Overall, inhaler-based treatments remain a cornerstone for effective cough management across different respiratory conditions.
Sources and full results
Most relevant research papers on this topic
Does the type of Inhaler matter in cough variant or cough predominant asthma?
Changing from a MDI to a DPI inhaler combined with inhalation training may lead to better asthma control and reduced cough severity in patients with cough variant or cough predominant asthma.
Patient response to the management during the acute presentation of cough variant Asthma: Retrospective cohort study
Budesonide-formoterol inhaler therapy significantly improves cough symptoms in patients with cough variant asthma, providing valuable information for optimizing patient care.
High-dose inhaled beclomethasone treatment in patients with chronic cough: a randomized placebo-controlled study.
High-dose inhaled beclomethasone effectively reduced chronic cough symptoms in a subgroup of patients without correlation to atopy or airway hyperresponsiveness.
DOI